Related references
Note: Only part of the references are listed.Prognostic Factors for Survival in Patients With Unresectable Pancreatic Cancer
Andreas Weber et al.
PANCREAS (2010)
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer.: Definitive results of the 2000-01 FFCD/SFRO study
B. Chauffert et al.
ANNALS OF ONCOLOGY (2008)
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
Viviane Hess et al.
LANCET ONCOLOGY (2008)
Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation
Sunil Krishnan et al.
CANCER (2006)
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer
Volker Heinemann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer:: Results of a GERCOR and GISCAD phase III trial
C Louvet et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Pancreatic cancer: Basic and clinical aspects
G Schneider et al.
GASTROENTEROLOGY (2005)
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
E Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine
C Ziske et al.
BRITISH JOURNAL OF CANCER (2003)
Prognostic factors in the palliation of pancreatic cancer
FJF Engelken et al.
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY (2003)
Prognostic factors in pancreatic carcinoma - Serum LDH levels predict survival in metastatic disease
F Tas et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2001)
Share Paper
